Abstract | BACKGROUND: METHODS: A total of 90 patients who presented to CCU of Khyber Teaching Hospital. Peshawar with USA or NSTEMI, from June 2008 to June 2009, were enrolled into the study. An equal number of patients were randomly assigned to one of the three arms for 5 days each: Group A received enoxaparin, group B received dalteparin and group C received UFH. The primary end points of the study were all cause mortality, STEMI, refractory USA, recurrent USA or a major bleed. The secondary end point was minor bleeding. RESULTS: At the end of the study, there were 2 deaths each in the dalteparin and UFH group, whereas no such event was recorded in the enoxaparin group. Two patients had STEMI in the UFH group but none in the other two groups. CONCLUSION:
|
Authors | Mushtaq Ahmed, Mohammad Tariq, Lubna Noor, Shahah Ud Din, Mohammad Hafizullah |
Journal | Journal of Ayub Medical College, Abbottabad : JAMC
(J Ayub Med Coll Abbottabad)
2011 Jul-Sep
Vol. 23
Issue 3
Pg. 60-3
ISSN: 1025-9589 [Print] Pakistan |
PMID | 23272437
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anticoagulants
- Enoxaparin
- Heparin
- Dalteparin
|
Topics |
- Acute Coronary Syndrome
(drug therapy)
- Adolescent
- Adult
- Anticoagulants
(therapeutic use)
- Dalteparin
(therapeutic use)
- Enoxaparin
(therapeutic use)
- Female
- Heparin
(therapeutic use)
- Humans
- Male
- Young Adult
|